Bar Harbor Trust Services reduced its position in shares of Johnson & Johnson (NYSE:JNJ – Get a rating) by 0.1% in Q1, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor held 100,400 shares of the company after selling 107 shares during the period. Johnson & Johnson accounts for approximately 5.4% of Bar Harbor Trust Services’ portfolio, making it its largest holding. Bar Harbor Trust Services’ holdings in Johnson & Johnson were worth $17,794,000 when it last filed with the Securities and Exchange Commission.
Other institutional investors also bought and sold shares of the company. Winthrop Advisory Group LLC increased its position in Johnson & Johnson by 3.7% during the first quarter. Winthrop Advisory Group LLC now owns 9,090 shares of the company worth $1,611,000 after buying 325 additional shares in the last quarter. Allied Investment Advisors LLC increased its position in Johnson & Johnson by 8.2% during the first quarter. Allied Investment Advisors LLC now owns 47,721 shares of the company worth $8,458,000 after buying 3,635 additional shares in the last quarter. RB Capital Management LLC increased its position in Johnson & Johnson by 1.8% during the first quarter. RB Capital Management LLC now owns 9,626 shares of the company worth $1,706,000 after purchasing an additional 169 shares in the last quarter. Ulland Investment Advisors LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $296,000. Finally, Matisse Capital increased its position in Johnson & Johnson by 9.0% during the first quarter. Matisse Capital now owns 1,820 shares of the company worth $323,000 after buying 150 more shares in the last quarter. 68.78% of the shares are currently held by hedge funds and other institutional investors.
In other Johnson & Johnson news, an insider William Haiti sold 29,699 shares of the company in a transaction dated Thursday, April 21. The shares were sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the completion of the transaction, the insider now owns 80,236 shares of the company, valued at $14,729,724.88. The sale was disclosed in a filing with the SEC, accessible via the SEC website. Also, CAD Robert J. Decker sold 8,462 Johnson & Johnson shares in a trade that took place on Thursday, May 26. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company, valued at approximately $2,785,140. Disclosure of this sale can be found here. In the past 90 days, insiders have sold 78,161 shares of the company valued at $13,895,302. Company insiders own 0.35% of the company’s shares.
NYSEJNJ opened at $176.94 on Wednesday. The company has a debt ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. The company has a 50-day simple moving average of $177.67 and a 200-day simple moving average of $173.59. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The stock has a market capitalization of $465.60 billion, a PE ratio of 23.85, a PEG ratio of 3.61 and a beta of 0.66.
Johnson & Johnson (NYSE:JNJ – Get a rating) last reported results on Tuesday, April 19. The company reported earnings per share of $2.67 for the quarter, beating the consensus estimate of $2.60 by $0.07. The company posted revenue of $23.43 billion in the quarter, compared to $23.62 billion expected by analysts. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The company’s revenue increased 5.0% year-over-year. In the same quarter last year, the company earned earnings per share of $2.59. Research analysts expect Johnson & Johnson to post earnings per share of 10.23 for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, June 7. Shareholders of record on Tuesday, May 24 received a dividend of $1.13 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date was Monday, May 23. This represents a dividend of $4.52 on an annualized basis and a yield of 2.55%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 60.92%.
JNJ has been the subject of several research analyst reports. Morgan Stanley lowered its price target on Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating on the stock in a Wednesday, April 6 research report. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong buy” rating in a Tuesday, May 17 research report. Citigroup lowered its price target on Johnson & Johnson from $210.00 to $205.00 in a Tuesday, May 17 research report. Sanford C. Bernstein downgraded Johnson & Johnson from an “outperforming” rating to a “market performing” rating and raised its price target for the company from $180.00 to $183.00 in a report of research from Wednesday, March 16. Finally, the Goldman Sachs Group raised its price target on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a Tuesday, April 12 research report. Four analysts gave the stock a hold rating, six gave the company a buy rating and one gave the company a strong buy rating. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $190.50.
Johnson & Johnson Profile (Get a rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.
Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.